​

ENDRA Life Sciences (NDRA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NDRA Stock Rating

ENDRA Life Sciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

NDRA Price Target Upside V Benchmarks

TypeNameUpside
StockENDRA Life Sciences-
SectorHealthcare Stocks 24.81%
IndustryDiagnostics & Research Stocks22.17%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.66$3.66$3.66
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-1---1
May, 25-1---1
Apr, 25-1---1
Mar, 25-1---1
Feb, 25-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 08, 2022H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-8K $-6K $-5K $-3K $-2K $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25
Dec 21Dec 22Dec 23Dec 24Dec 25
Reported$-5.47$-4.57$-1.11$-56.94-
Avg Forecast$-280.00$-7.70K$-3.24K$-47.46$-15.38
High Forecast$-280.00$-7.70K$-3.24K$-47.46$-15.38
Low Forecast$-280.00$-7.70K$-3.24K$-47.46$-15.38
Surprise %-98.05%-99.94%-99.97%19.97%-

Revenue Forecast

$100K $220K $340K $460K $580K $700K Dec 21 Dec 22 Dec 23 Dec 24 Dec 25
Dec 21Dec 22Dec 23Dec 24Dec 25
Reported-----
Avg Forecast$225.00K$700.00K$100.00K$100.00K$100.00K
High Forecast$225.00K$700.00K$100.00K$100.00K$100.00K
Low Forecast$225.00K$700.00K$100.00K$100.00K$100.00K
Surprise %-----

Net Income Forecast

$-70B $-56B $-42B $-28B $-14B $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25
Dec 21Dec 22Dec 23Dec 24Dec 25
Reported$-11.19M$-13.20M$-10.06M$-11.51M-
Avg Forecast$-2.53B$-69.59B$-29.26B$-428.90M$-138.99M
High Forecast$-2.53B$-69.59B$-29.26B$-428.90M$-138.99M
Low Forecast$-2.53B$-69.59B$-29.26B$-428.90M$-138.99M
Surprise %-99.56%-99.98%-99.97%-97.32%-

NDRA Forecast FAQ

Is ENDRA Life Sciences stock a buy?

ENDRA Life Sciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ENDRA Life Sciences is a favorable investment for most analysts.

What is ENDRA Life Sciences's price target?

ENDRA Life Sciences's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $3.66.

How does ENDRA Life Sciences stock forecast compare to its benchmarks?

ENDRA Life Sciences's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the diagnostics & research stocks industry (22.17%).

What is the breakdown of analyst ratings for ENDRA Life Sciences over the past three months?

  • June 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ENDRA Life Sciences’s EPS forecast?

ENDRA Life Sciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-15.38, marking a -72.99% decrease from the reported $-56.94 in 2024..

What is ENDRA Life Sciences’s revenue forecast?

ENDRA Life Sciences's average annual revenue forecast for its fiscal year ending in December 2025 is $100K, reflecting a 0% decrease from the reported $0 in 2024.

What is ENDRA Life Sciences’s net income forecast?

ENDRA Life Sciences's net income forecast for the fiscal year ending in December 2025 stands at $-139M, representing an 1107.78% increase from the reported $-11.508M in 2024.